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Abstract An efficient acetic acid catalysed reaction has been devel-
oped for the synthesis of 4-aryl substituted pyrrolo[1,2-a]quinoxalines
from readily available starting materials. A range of structures have
been synthesised in very good to excellent yields. The one-pot reaction
proceeds through imine formation, cyclisation followed by air oxida-
tion.
Key words pyrrolo[1,2-a]quinoxaline, catalysis, Pictet–Spengler reac-
tion, 1-(2-aminophenyl)pyrroles, biological heterocycles
The pyrrolo[1,2-a]quinoxaline scaffold is present in var-
ious heterocyclic compounds that exhibit an extensive
range of pharmacological profiles.1 In particular, substitu-
tion at the C-4 position of the pyrroloquinoxaline motif re-
sults in derivatives that possess biological activities such as
anticancer,2 antimalarial,3 and antiproliferative effects.4 Ad-
ditionally, these structures have been reported as inhibitors
of the human protein kinase CK2,5 glucagon receptor ago-
nists,6 and 5HT3 receptor agonists,7 and have been applica-
ble in the synthesis of GABA benzodiazepine receptor ago-
nists and antagonists.8 Some of these compounds have also
exhibited unique fluorescence properties, enabling uses for
amyloid fibril detection.9 For this reason, the efficient syn-
thesis of 4-substituted pyrrolo[1,2-a]quinoxalines has
gained much attention and is a highly desirable target in
drug discovery. Various methods have been developed for
the synthesis of 4,5-dihydropyrrolo[1,2-a]quinoxalines and
unsubstituted pyrrolo[1,2-a]quinoxalines;10 however, a sur-
vey of the literature revealed that few methods have been
reported for the more active 4-substituted derivatives
(Scheme 1).11 A rare one-pot iron-promoted reduction of 1-
(2-nitrophenyl)pyrroles, oxidation of alcohols followed by
cyclisation and heterocycle oxidation in a cascade has been
reported by Pereira.12 A novel activated carbon/water cata-
lytic system has recently been reported by Wang between
1-(2-nitrophenyl)pyrroles and aryl amines for the synthesis
of pyrrolo[1,2-a]quinoxalines.13 The radical addition of iso-
cyanides has been reported by Hilton.14 However, the most
common methods to synthesise 4-substituted derivatives
involve the reduction of 1-(2-nitrophenyl)pyrroles to the
corresponding amino derivatives.15 Treatment of the amino
group with acid chlorides to form the corresponding acet-
amides followed by intramolecular cyclisation under Bischler–
Napieralski conditions formed the 4-substituted pyr-
rolo[1,2-a]quinoxaline core.16 Another approach involved
the condensation between amino derivatives and aldehydes
followed by oxidation of the 4,5-dihydro pyrroloquinoxal-
ine intermediate.17 A modified Pictet–Spengler reaction us-
ing benzotriazole followed by oxidation with MnO2 has
been reported as a one-pot procedure to construct 4-
arylpyrrolo[1,2-a]quinoxalines.18 Huo reported a metal-free
variation of the Pictet–Spengler reaction meditated by
TEMPO oxoammonium salts.19 Recently, Krishna reported a
one-pot copper-catalysed synthesis of pyrrolo[1,2-a]qui-
noxalines from 1-(2-aminophenyl)pyrroles and alde-
hydes.20 These multistep syntheses have led to moderate
yields and, in most cases, require the use of toxic reagents.
Therefore, it is highly desirable to develop an efficient, non-
toxic and convenient approach for the synthesis of 4-substi-
tuted pyrroloquinoxalines.
To identify the optimal reaction conditions, commer-
cially available 1-(2-aminophenyl)pyrrole and benzalde-
hyde were initially used as model substrates. Reaction in
the absence of an acid catalyst resulted in neither com-
pounds 3a nor 4a (Table 1, entry 1). The efficiency of differ-
ent acid catalysts was explored at 60 °C (entries 2–6) under
an inert atmosphere. In the presence of concentrated hy-
drochloric acid or p-TSA no reaction was observed, and only
small amounts of the desired cyclised product 3a was ob-© 2019. Thieme. All rights reserved. Synlett 2019, 30, A–E
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l.tained with zinc chloride and trifluoroacetic acid. Reaction
with acetic acid resulted in 55% yield of 3a, with small
amounts of the 4,5-dihydropyrroloquinoxaline 4a observed
by NMR analysis. The 4,5-dihydropyrroloquinoxaline 4a ox-
idised to 3a on standing at room temperature, as observed
by Verma.18 Further optimisation in the presence of air re-
sulted in the greatest yield of 3a at 89%, suggesting air oxi-
dation was promoting aromaticity. No obvious improve-
ments were observed when screening different solvents
(entries 8–11). The reaction was explored at different tem-
































Table 1  Optimisation of Reaction Conditionsa
Entry Acid Atmosphere Solvent Temp. (°C) Yield of 3a (%)
 1 – N2 MeOH 60 –
 2 pTSA N2 MeOH 60 –
 3 ZnCl2 N2 MeOH 60 14
 4 HCl N2 MeOH 60 –
 5 AcOH N2 MeOH 60 55
 6 TFA N2 MeOH 60  9
 7 AcOH air MeOH 60 89
 8 AcOH air THF 60 51
 9 AcOH air EtOAc 60 43
10 AcOH air MeCN 60 61
11 AcOH air toluene 60 58
12 AcOH air MeOH 25 20
13b AcOH air MeOH 80 75
14c AcOH air MeOH 60 trace
15d AcOH air MeOH 60 50
a Reactions were carried out using 1-(2-aminophenyl)pyrrole (1 equiv) and benzaldehyde (1 equiv).
b Experiment was carried out in a sealed tube.
c Experiment was carried using 5 mol% catalyst.
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l.peratures (entries 7, 12, and 13), and a mixture of 3a and 4a
was observed at 25 °C.21 The highest-yielding reaction was
observed at 60 °C. When the catalyst loading was halved to
5 mol% only a trace amount of the desired product was ob-
served (entry 14), with the 4,5-dihydro pyrroloquinoxaline
4a isolated as the major product. When the stoichiometry
of benzaldehyde was increased five-fold, the yield de-
creased to 50% and isolation was problematic (entry 15).
With optimised conditions in hand, the reaction was
further studied to extend the scope and generality of the
protocol and to afford a series of 4-arylpyrrolo[1,2-a]qui-
noxaline derivatives in good to excellent yields (Table 2).
Initially, electron-rich benzaldehydes were reacted to pro-
vide the corresponding pyrroloquinoxalines 3b–d in 83–
85% yield. In the presence of electron-withdrawing nitro
groups, the position of the substituent affected the out-
come of the reaction. Use of 3-nitrobenzaldehyde resulted
in the 4,5-dihydropyrroloquinoxaline in a low yield; where-
as the p-substituted reactant resulted in 82% yield of 3f. En-
couraged by this result, a series of halogen-substituted
benzaldehydes was examined, and the resultant o- and p-
substituted products 3h and 3j were produced in 87% and
84% yield, respectively. However, the m-substituted halogen
benzaldehydes 2g and 2i resulted in an inseparable mixture
of the aromatised product 3g and 3i, and the 4,5-dihydro-
pyrroloquinoxaline 4g and 4i. Thiophene-2-carboxaldehyde
and further functionalised benzaldehydes were efficiently
employed to produce pyrroloquinoxalines 3k–o in 83–88%
yield.
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3b 83% 3d 85%
3e – 3g –
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l.Next, the substrate scope with substituted anilines was
investigated (Table 3). Use of electron-rich anilines resulted
in excellent yields of pyrroloquinoxalines 3p–u.
Unfortunately, no reaction was observed when a CF3
group was appended to the aniline ring. To explore elec-
tron-deficient substrates further, methyl benzoates 1t and
1u were tested (Table 3). When the ester group was in the
same position as the trifluoromethyl group (1s) no reaction
was observed. Compounds 3s and 3t possess electron-defi-
cient groups in the para position to the pyrrole and were
unreactive as a result of conjugation of the pyrrole nitrogen
lone pair of electrons into the electron-withdrawing
group.23 This was confirmed when ester 1u was prepared
by using a known procedure and produced the correspond-
ing pyrroloquinoxaline 3u in excellent yield.
Based on previous reports, a plausible mechanism for
the synthesis of pyrrolo[1,2-a]quinoxaline is proposed in
Scheme 2. The reaction occurs by initial condensation of
aminophenylpyrrole 1 and aldehyde 2 to afford the imini-
um intermediate 5. This undergoes intramolecular electro-
philic addition in a Pictet–Spengler type reaction to give di-
hydro derivative 4, which oxidises in the presence of air to
the corresponding aromatic pyrroloquinoxaline 3.
In summary, a facile method for the synthesis of pyrro-
lo[1,2-a]quinoxalines 3 using the Pictet–Spengler reaction
has been developed by using a catalytic amount of acetic
acid.22 A range of compounds has been prepared in high
yields under mild conditions. It has been shown that the
position of the electron-withdrawing groups is crucial;
when the group is in a deactivating position the reaction
does not proceed due to conjugation with the pyrrole nitro-
gen lone pair of electrons. Synthetic applications to biologi-
cally active compounds using this methodology are under
way.






















3p 85% 3q 86% 3r 86%
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